Validation of the Pretreatment Neutrophil-Lymphocyte Ratio as a Predictor of Overall Survival in a Cohort of Patients With Pancreatic Ductal Adenocarcinoma
Menée sur une cohorte chinoise incluant 381 patients atteints d'un adénocarcinome canalaire du pancréas traité entre 2004 et 2011, cette étude évalue l'association entre le rapport neutrophiles/lymphocytes avant traitement et la survie globale des patients
Objectives : The circulating neutrophil-lymphocyte ratio (NLR) has been shown to be a prognostic factor for a variety of tumors. In this study, we evaluated the prognostic significance of NLR in a large cohort of Chinese patients with pancreatic ductal adenocarcinomas (PDACs).
Methods : A total of 381 patients with PDAC who underwent potentially curative surgery were recruited from 2 centers in Shanghai, China, between January 2004 and September 2011. Analysis of overall survival (OS) was performed using the Kaplan-Meier and log-rank tests and the Cox proportional hazards regression model.
Results : The most optimal cutoff of NLR was NLR 2.0 or greater, and the NLR was divided into 2 groups: high (>=2.0) and low (<2.0). The high NLR (>=2.0) was associated with advanced UICC (Union for International Cancer Control) stages, p T stage, lymphoid node invasion, and poorer tumor differentiation. Multivariate analysis identified increased NLR as an independent prognostic factor for OS (hazard ratio = 1.51; 95 % confidence interval, 1.15-1.99; P = 0.003). Furthermore, neutrophil counts rather than lymphocyte counts were associated with OS of PDAC.
Conclusions : The pretreatment NLR is a simple and useful potential biomarker for OS in patients with PDAC after curative resection.
Pancreas , résumé, 2013